NCT05463770View on ClinicalTrials.gov

A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 30, 2022

Primary Completion Date

August 22, 2023

Study Completion Date

August 22, 2023

Conditions
Schizophrenia
Interventions
DRUG

SEP-363856

SEP-363856, 12.5 mg, 25 mg, and 50 mg tablets. The dose taken at the same time each day, in the evening and in the morning. Multiple tablets may be required to achieve a single dose.

Trial Locations (8)

33016

Galiz Research, Hialeah

44720

Neuro-Behavioral Clinical Research, Inc., North Canton

72211

Woodland International Research Group, LLC, Little Rock

72758

Woodland Research Northwest, LLC, Rogers

75080

Pillar Clinical Research, LLC, Richardson

90806

Collaborative Neuroscience Research, LLC, Long Beach

91763

Catalina Research Institute LLC, Montclair

92102

CNRI - San Diego LLC, San Diego

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY